Patients colonized with AMR pathogens showed high risk for infection with the same pathogen for up to 2 years, indicating a time window for decolonization interventions.

Dalba vancin and oritavancin have shown bactericidal activity against MRSA, VRSA, VRE, and DRSP and are undergoing the final stages of clinical trials (Bradley, 2005; Hoffman-Roberts et al., ...

While the prevalence of VISA and VRSA remains low, concerns about vancomycin resistance and the lack of a clinical or bacteriological response with as many as 18% of MRSA isolates with a ...

A new study reveals that diabetes significantly accelerates the emergence and spread of antibiotic-resistant Staphylococcus ...

Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA (National Medical ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...

Texas A&M researchers have found that curcumin, when activated by light, can weaken antibiotic-resistant bacteria, restoring ...

“We’re seeing a lot of MRSA pneumonia and really bad MRSA pneumonia after influenza, so what we call necrotizing, where you’re getting a lot of destruction of the lung tissue,” said Dr ...

An outbreak of the deadly superbug MRSA, which is resistant to many antibiotics, has been declared at Victoria Hospital this week. MRSA, which stands for methicillin-resistant Staphylococcus ...

The MRSA superbug has evolved into 'fitter' strains which could prove even more resistant to treatment, a leading scientist warned on Tuesday. Professor Hajo Grundmann, a world expert in ...

Antibiotics are powerful, fast-acting medications designed to eradicate bacterial infections. However, in recent years, their dependability has waned as antibiotic resistant bacteria continues to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...